Drugs / in vivo CAR-T drug based on LNP-mRNA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07362758 | Jan 2026 → Jan 2028 expected | autoimmune disease | Xinqiao Hospital of Chongqing | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07349849 | Dec 2025 → Jan 2028 expected | B-cell neoplasm | Xinqiao Hospital of Chongqing | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | in vivo CAR-T drug based on LNP-mRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07349849 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA Therapeutic Drug Targeting CD19” NCT07349849 ↗ |
| Route | Intramuscular | “deliver them to the body through intravenous or intramuscular injection” NCT07349849 ↗ |
| Route | Intravenous | “deliver them to the body through intravenous or intramuscular injection” NCT07349849 ↗ |
| Target | CD19 | “mRNA Therapeutic Drug Targeting CD19” NCT07349849 ↗ |